Searched for
NICHE MOLECULES
Amit Khurana backs LTIMindtree, OFSS and eClerx as tactical betsAmit Khurana of Dolat Capital has upgraded India's IT sector, citing depressed valuations and rupee depreciation as key drivers. He believe...- If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil KhorakiwalaWockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected t...
- RPG Life Sciences bets big on API business, eyes GLP-1 entry by August-SeptemberRPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company a...
- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
- Suven Pharma shares in focus after Q3 profit jumps 78% YoY, revenue up 40%Suven Pharma reported a 78% YoY rise in Q3FY25 net profit to Rs 83.3 crore, with revenue growing 40% to Rs 307.2 crore, driven by its CDMO ...
- Suven Pharma Q3 Results: Net profit surges 78% to Rs 83 crore, revenue up 40%Suven Pharma, backed by Advent, reported a 78% year-on-year rise in net profit to Rs 83.3 crore for Q3FY25 driven by strong demand and busi...
- Concord Biotech's niche strengths seen buoying earnings: AnalystsShares of the Ahmedabad-based biopharma company, which listed a few weeks ago at a more than 20% premium, have notched another 9% gain sinc...
- Anupam Rasayan touches 52-week high on US order winThis is the third big order for Anupam in a month taking the cumulative value of contracts to around ₹2,500 crore. The total order backlog ...
- Amit Rajan on why pharma MNCs are beating Indian counterpartsPatent protection, ban on fixed dose combinations among factors helping pharma MNCs
- Local pharma formulators to benefit from new USFDA generic guidance: ReportThis will help domestic pharma formulators with pending ANDA approvals to reduce review cycles and expedite approvals, says a weekend repor...
- Indian pharma industry facing growth headwinds: ICRA"In spite of these ongoing challenges, several Indian pharma companies are increasing their R&D spend, targeting pipeline of specialty drug...
- Mankind Pharma to invest Rs 150 crore in Paonta Sahib plantThe growth of nutraceuticals market in India accounts for around 1.5 per cent of the global market which is currently estimated at $4,182 b...
- Piramal Healthcare to invest $11 mn in UK facilityWork on the new suite, which will house formulation, packaging coating and tableting equipment, will commence at the end of 2013.
- Brokers’ picks: Glenmark, Bajaj CorpBajaj Corp (BJCorp) has acquired the personal care brand No Marks which primarily operates in the niche category of Anti Marks.
- How Piramal Healthcare is trying to build an entire business around discovering new drugsPiramal's game plan is to add to this portfolio by buying more molecules in late stages of development in niche segments.
- CRISIL assigns 4/5 grade to Glenmark Generics IPOCRISIL has assigned CRISIL IPO Grade "4/5" to the proposed initial public offer of Glenmark Generics (GGL).
- 'There will be consolidation in generics'We are looking at acquisitions in the US market to make an inroad. We are also concentrating on developing the BRIC countries and building ...
- Nicholas Piramal may offer research arm stake to PEsMumbai-based drug major Nicholas Piramal India (NPIL) is in talks with private equity funds for the sale of a ‘small’ stake in its research...
- Ranbaxy forays into authorised generics in USPharmaceutical major Ranbaxy Laboratories on Monday said it has commercialised its first authorised generic product, Isoptin SR - an anti h...
- Torrent Pharma launches 3 new speciality armsAhmedabad-based Torrent Pharmaceuticals on Friday said it has launched three new speciality divisions to cater to niche therapeutic areas o...
Load More
